Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | BTK and PLCG2 mutations in CLL patients taking ibrutinib

Lydia Scarfò • 2 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses Bruton’s tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCG2) mutations in chronic lymphocytic leukemia (CLL) patients receiving ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lydia Scarfò

1:56
Defining success in CLL
Lydia Scarfò • 8 Oct 2023
2:00
Prevention of TLS with venetoclax-based regimens
Lydia Scarfò • 8 Oct 2023
1:28
Challenges with defining fitness in CLL & important comorbidities to consider when selecting therapy
Lydia Scarfò • 8 Oct 2023
2:08
Choosing between continuous versus fixed-duration therapy in CLL
Lydia Scarfò • 8 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals